For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for DexCom, Inc. (DXCM) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-09-21): Designation Watch · Gem Score -9 (−100…+100 Quality+Value blend) · Quality 65 · Value -58 · Sentiment -44 (timing only, not weighted) · Composite fair value $39.13 vs $88.96 at analysis
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
DexCom, Inc.
DXCM NASDAQDexCom Inc. is a medical device company focused on continuous glucose monitoring systems for diabetes and metabolic health. Dexcom develops wearable biosensors, transmitters, receivers, and software that provide real-time glucose readings, trend data, and alerts to help users and clinicians monitor glucose levels without routine fingerstick testing. Its current product lineup includes Dexcom G7, Dexcom G7 15 Day, Dexcom G6, Dexcom ONE+, Stelo, Dexcom Share, and Dexcom Follow, along with digital tools and remote monitoring features that support daily diabetes management. The company serves people with diabetes, adults with prediabetes and type 2 diabetes who do not use insulin, and healthcare professionals across the United States and international markets. Headquartered in San Diego, California, DexCom plays a significant role in the diabetes care technology market through its focus on connected glucose sensing and data-sharing solutions.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 2.09
Total Equity: N/A
Shares: 405,500,000
Total Debt: $0.00
Cash: $917.70M
EBITDA: $1.16B
Total Debt: $0.00
Cash: $917.70M
Revenue: $4.66B
Revenue: $4.66B
Revenue: $4.66B
Total Equity: N/A
Tax Rate: 23.2%
Equity: N/A
Total Debt: $0.00
Cash: $917.70M
Current Liabilities: $2.14B
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: N/A
Shares: 405,500,000
Shares: 405,500,000
CapEx: -$363.50M
Shares: 405,500,000
Stock Price: $89.16
Net Income: $836.30M
Industry Benchmarks
Income Statement (Annual)
Last updated: Aug 26, 2026 1:24am (26d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $2.4B | $2.9B | $3.6B | $4.0B | $4.7B |
| Cost of Revenue | $768.0M | $1.0B | $1.3B | $1.6B | $1.9B |
| Gross Profit | $1.7B | $1.9B | $2.3B | $2.4B | $2.8B |
| Operating Expenses | $1.4B | $1.5B | $1.7B | $1.8B | $1.9B |
| Operating Income | $265.8M | $391.2M | $597.7M | $600.0M | $911.8M |
| Net Income | $154.7M | $341.2M | $541.5M | $576.2M | $836.3M |
| EBITDA | $367.8M | $547.1M | $783.7M | $817.7M | $1.2B |
| EPS | $0.41 | $0.88 | $1.40 | $1.46 | $2.14 |
| EPS (Diluted) | $0.40 | $0.82 | $1.30 | $1.42 | $2.09 |
Balance Sheet (Annual)
Last updated: Aug 26, 2026 1:00am (26d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $1.1B | $642.3M | $566.3M | $606.1M | $917.7M |
| Total Current Assets | $3.7B | $3.7B | $4.4B | $4.3B | $4.0B |
| Total Assets | $4.9B | $5.4B | $6.3B | $6.5B | $6.3B |
| Current Liabilities | $720.8M | $1.8B | $1.6B | $2.9B | $2.1B |
| Long-Term Debt | — | — | — | — | — |
| Total Liabilities | $2.6B | $3.3B | $4.2B | $4.4B | $3.6B |
| Total Equity | — | $2.1B | $2.1B | $2.1B | — |
| Retained Earnings | -$47.4M | $479.9M | $1.0B | $1.6B | $2.4B |
Cash Flow (Annual)
Last updated: Aug 26, 2026 1:24am (26d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $442.5M | $669.5M | $748.5M | $989.5M | $1.4B |
| Capital Expenditure | -$389.2M | -$364.8M | -$236.6M | -$358.8M | -$363.5M |
| Free Cash Flow | $53.3M | $304.7M | $511.9M | $630.7M | $1.1B |
| Acquisitions (net) | -$30.2M | -$3.9M | $0 | $0 | — |
| Net Debt Issued / (Repaid) | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | -$557.7M | -$688.7M | -$750.0M | -$500.0M |
| Net Change in Cash | $235.4M | -$410.3M | -$75.8M | $39.8M | $311.8M |
Growth Trends (YoY %)
Last updated: Aug 26, 2026 1:24am (26d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +18.8% | +24.5% | +11.3% | +15.6% |
| Gross Profit Growth | +12.1% | +21.5% | +6.5% | +14.9% |
| Operating Income Growth | +47.2% | +52.8% | +0.4% | +52.0% |
| Net Income Growth | +120.6% | +58.7% | +6.4% | +45.1% |
| EBITDA Growth | +48.7% | +43.2% | +4.3% | +42.3% |
Deep Analysis
Risk : Reward — upside vs downside from this company's own quarters
Computed 2026-09-18 02:42A +1σ run of quarters pays -62%; a −1σ run costs 76%. Ratio -0.8:1 (μ 14.9%, σ 5.4% , 16 pairs).
Older method (repeat-worst-quarter): -0.8 : 1
| Case | Growth | Margin | Fair value | vs price ($88.96) |
|---|---|---|---|---|
| Bull — recovery | +24% | 23.1% | $39.13 | -56% |
| Base — stabilizes | +16% | 20.1% | $27.43 | -69% |
| Bear — keeps slipping | +8% | 17.1% | $18.80 | -79% |
| Stress — last quarter repeats | +13% | 22.1% | $27.18 | -69% |
| Upside — a +1σ run of quarters (v2) | +20% | 22.1% | $33.60 | -62% |
| Stress — a −1σ run of quarters (v2) | +9% | 19.3% | $21.71 | -76% |
Narrative Economics
market-narrative step).
Growth Outlook
Analyzed 2026-08-27 09:42The question every valuation on this page silently assumes: is this company likely to grow? Judged forward — the business, its category, the world — against what's already printed.
Claude Reading
Looking at the raw print first: TTM revenue is roughly $4.97B (Q3'25 through Q2'26), up from $4.66B FY2025, with the latest quarter at $1.31B growing ~13% YoY against $1.16B. That's a clear deceleration from the 15.6% "recent YoY" figure the momentum layer cites — the two most recent quarters show sequential growth but the YoY comps are compressing as Abbott's Libre 3 gains share. Margins are the more interesting story: gross margin sits at 60%, operating margin ~20%, and the quarterly net margin oscillates violently (10.2% → 23.5% → 15.5% → 21.2% → 16.7% → 19%) — that volatility screams tax/one-time items, not operational leverage. FCF of $1.08B on $4.66B revenue is a genuine 23% FCF margin, and with only $6.7M of debt against $918M cash, the balance sheet is pristine. This is a real business, not a story stock.
Where I part company with the synthesis: a $42 fair value on a company generating $1.08B FCF, growing 13-15%, with 60% gross margins and net cash, implies roughly 15x FCF for a category-leading medical device franchise. That's punitively cheap and probably wrong. At $89 and $33.6B market cap, EV/FCF is ~30x, and forward EV/FCF is closer to 24-26x if FCF grows in line with earnings. For a business with DexCom's moat characteristics (Type 1 diabetes stickiness is genuinely near-monopolistic; the "Stelo optionality" is free), that's expensive but not egregious. The synthesis's -52.8% call is the kind of DCF output you get when you plug conservative terminal growth into a company whose durable growth rate is contested — it's mechanically defensible but commercially naive. Thesis Evaluation's -11 score (essentially neutral) is closer to reality than the synthesis's screaming overvaluation.
The contrarian bear case the models under-weight: Abbott's Libre 3 Plus is genuinely competitive on accuracy and materially cheaper, and DexCom's Q1'25 revenue of $1.04B (down QoQ from $1.11B) revealed a US pharmacy channel disruption that management framed as transitory but which looks structural in hindsight — Q1'26 rebounded to $1.19B but that's only 14% YoY, not the 20%+ this multiple demands. Insider activity is quietly telling: seven sales, one gift, zero opens buys across a month of transactions including a 26,756-share dump on 7/20. That's not "neutral" — that's insiders using strength to lighten. Stelo has shipped but there's no disclosed revenue contribution meaningful enough to bend the growth curve, and the "prediabetic TAM" thesis requires cash-pay consumers to sustain $40-70/month indefinitely — a bet against GLP-1 substitution effects that are already reshaping metabolic health economics.
My verdict: the synthesis is directionally right but numerically overshooting. This isn't a $42 stock; it's probably a $65-75 stock — worth 20-22x FCF for a decelerating-but-durable 13% grower with best-in-class margins and pristine balance sheet, but not 30x on contested TAM expansion. At $89 you're paying full narrative price with insiders selling into it and Abbott's competitive pressure intensifying. The Thesis Evaluation's framing — "market prices 59% growth that penetration math cannot support" — is the right shape of the argument even if the specific number is aggressive. I'd dissent from the synthesis's magnitude (fair value is not $42) but agree with its direction (overvalued). A patient buyer waits for a Q3 or Q4 miss that compresses the multiple to 20x FCF, which puts the stock in the low $60s. Momentum's "45% FCF CAGR" is a base-effect artifact from 2021's depressed FCF — do not extrapolate.
GPT Reading
DexCom looks less like a speculative “story stock” than the market-bear framing suggests, but it still does not look cheap at $88.96. The raw numbers show a business compounding with real operating leverage: revenue rose from $2.45B in 2021 to $4.66B in 2025, a near-doubling in four years, while net income climbed from $154.7M to $836.3M. That is not hype-driven financial engineering; it is a category leader converting scale into economics. Gross margin held at 60.1% in 2025, operating margin reached 19.6%, and net margin 17.9%, all while free cash flow hit $1.08B on $1.44B of operating cash flow. Even more important, the recent quarter trend is healthy, not broken: June 2026 revenue was $1.31B, up 15.6% from $1.16B a year earlier, and net income jumped 38.5% to $249.1M. On a trailing four-quarter view using the quarterly data provided, revenue is about $4.97B and net income about $1.00B, implying the stock is trading closer to 33-34x trailing earnings than the stale 42.6x annual metric suggests. For a dominant medtech franchise with net cash and double-digit top-line growth, that multiple is demanding but not absurd.
What stands out to me is that the business is clearly transitioning from “growth at any cost” to “scaled compounder,” and the market may be misclassifying it in both directions. The rule-based “mature earner” label is directionally right on the economics, but wrong if it implies growth is largely gone. Quarterly revenue moved from $994M in 3Q24 to $1.31B in 2Q26, and quarterly net margin expanded from roughly 13.5% to 19.0% over that span despite some normal quarter-to-quarter volatility. 2025 annual revenue grew 15.6% over 2024, and the first half of 2026 is running ahead of first half 2025 by roughly 14.7% ($2.50B versus $2.18B). That is not hypergrowth, but it is a very attractive combination: mid-teens revenue growth, 60% gross margins, rising profit conversion, and essentially no balance-sheet risk with just $6.7M of debt against $917.7M of cash. This is exactly the sort of profile that can hold a premium multiple for a long time, especially in medical devices where recurring consumables and embedded physician/payer workflows matter more than one-time hardware narratives.
The problem is that “can hold a premium multiple” is different from “worth almost 9x sales.” At a $33.6B market cap and roughly $32.7B enterprise value after net cash, DexCom is valued like a company that can sustain mid-teens growth for years while preserving or even expanding current margins. That may happen, but today’s numbers do not yet prove a step-change beyond that. Yes, earnings are scaling faster than revenue, but a 7.1x EV/revenue and 28.4x EV/EBITDA multiple leave limited room for payer friction, competition, or simple maturation. On 2025 free cash flow of $1.08B, the equity is around 31x FCF; on a rough trailing basis it is lower, but still rich for a company no longer growing 25%+. My read is that the stock is not the grotesque overvaluation some models imply with a $40 fair value, because those models are under-crediting the quality, balance sheet, and margin trajectory. But it is also not obviously mispriced to the upside. This is a very good company priced as a very good company, with some extra optionality already embedded.
The strongest pushback to my caution is straightforward: the recent data actually support multiple resilience better than I am giving credit for. Net income in the last four quarters totals nearly $1.0B, up sharply from $836M for full-year 2025, and quarterly margins have repeatedly printed in the high teens to low 20s. If DexCom can grow revenue from roughly $5.0B trailing toward $6.0B over the next 12-18 months while keeping net margins around 20%, earnings power could move into the $1.2B range quickly, which would make today’s price look more like high-20s forward earnings for a clean balance sheet medtech leader. A bull would also argue that insider selling here is not especially informative given the tiny lot sizes relative to market cap and the absence of debt risk. I weigh those points seriously; they are why I do not agree with an extreme bear case. But I still weigh them less heavily because the valuation already assumes execution stays near-flawless. Once a device company is above $4.5B in revenue, sustaining 15%+ growth gets structurally harder, and even mild deceleration can compress a premium multiple faster than earnings can grow into it.
What would change my mind either way is specific. I would turn more constructive if DexCom can post another two quarters with revenue growth still at or above 15%, while net margin holds near 18-20% and free cash flow continues to track comfortably above $1.1B annualized; that would support a case that the business deserves to trade through $95 and perhaps into the low $100s. I would turn outright bearish if growth slips toward 10-12% while margins flatten or fall, because at that point an 7x sales / 30x-ish earnings framework is too rich and I would expect the stock to de-rate toward the low $70s.
Grok Reading
DexCom’s financials describe a high-quality franchise that is still expanding, not a mature cash cow that has already peaked. Revenue climbed from $2.45B in 2021 to $4.66B in 2025, with the most recent quarters still printing mid-teens growth ($1.31B in the June 2026 quarter versus $1.16B a year earlier, roughly +13%). What stands out harder than the top line is the earnings and cash conversion: net income rose from $155M to $836M over the same stretch, operating margin reached 19.6%, and free cash flow hit $1.08B against only $363M of capex and essentially zero net debt ($6.7M total debt versus $918M cash). Trailing FCF yield at a $33.6B enterprise is thin at ~3%, yet the absolute cash engine and 60% gross margin give the business real durability. The rule-based “mature earner” label understates the still-elevated earnings CAGR (24%) and FCF CAGR (45%); this is a growth compounder whose margins are still climbing.
The price, however, embeds a far more aggressive future than the recent run-rate supports. At $88.96 the stock trades at 42.6× earnings, 7.7× sales and 28× EV/EBITDA. Those multiples only clear if CGM penetration keeps compounding at high teens or better while Stelo/OTC metabolic sensors open a large non-diabetic TAM and competitive intensity from Abbott stays muted. Recent revenue growth has already settled into the low-to-mid teens and the secondary signals flag deceleration; the thesis layer’s claim that the market is capitalizing something like 59% annual FCF growth is directionally right even if the precise figure is model-dependent. A DCF anchored near $42 is too punitive for a clean-balance-sheet device leader, but even a generous 28–30× forward earnings on continued mid-teens growth and further margin lift struggles to justify much above the mid-$60s. The $89 print is therefore a narrative premium—platform lock-in plus 5–10× TAM expansion—rather than a cash-flow price.
The strongest counter-argument is that the installed-base economics and switching costs are under-appreciated by simple multiples. Believers will correctly note that G7 clinical integration, payer contracts and patient habit create real stickiness, that operating leverage is still visible (net margin expanded from 10% to 19% in six quarters), and that FCF quality is pristine. If Stelo gains consumer traction and reimbursement creeps into prediabetes, the same 15% revenue trajectory could persist longer than a pure diabetes-penetration model allows, and a 35–40× earnings multiple would then look less extreme. Insider selling has been routine rather than panicked, and the fortress balance sheet gives management optionality for buybacks or tuck-ins. Those points keep me from calling the equity a short; they do not close a nearly 100% gap between cash-flow value and market price.
I would reverse to neutral or constructive on two concrete developments: sustained quarterly revenue growth re-accelerating above 20% for three consecutive quarters with clear Stelo contribution, or evidence that gross margin can push through the mid-60s while operating margin holds above 25% on the larger base. Absent that, multiple compression is the base case.
Big-3 Panel — where each AI stands
Advanced Analysis Forensic deep-dive · separate lenses
DexCom has scaled revenue from $2.45B (2021) to $4.66B (2025), a ~17% CAGR, while FCF has inflected from $53M to $1.08B and net income from $155M to $836M. Operating margin expanded to 19.6% in 2025 and OCF/NI of 1.93x with accruals of -6.2% of assets, Beneish M of -2.7, and Altman Z of 7.71 all point to genuinely high earnings integrity. The balance sheet is comfortable: $918M liquid cash, $911M net cash, and free cash flow that exceeds capex needs, so the business does not depend on capital markets. Capital discipline is respectable for a growth medtech: diluted shares actually declined from 427.5M (2022) to 405.5M (2025), SBC is only 3.4% of revenue, and buybacks are running 3.46x SBC, so per-share value is being protected rather than eroded. Insider activity is small routine selling ($2.7M over 12 months, no buys) - not a red flag at this scale but not a vote of conviction either. The blemish is gross margin: 68.6% (2021) to 64.7% to 63.2% to 60.5% to 60.1% - a steady ~850 bps erosion over four years even as revenue scaled. Operating leverage has masked it at the operating line, but this is a real durability question about pricing power, mix (Stelo/OTC), payer dynamics, or manufacturing cost that the modules do not capture.
Verify before trusting this (6)
- Root cause of the 850 bps GM compression 2021-2025: Stelo/OTC mix, GLP-1 headwinds, payer/pricing, or manufacturing scale
- Segment/geographic revenue mix and whether international or OTC is diluting corporate GM
- Customer/payer concentration and reimbursement risk disclosed in 10-K
- Convertible or long-term debt terms (gross debt vs. $918M cash to confirm net cash of $911M)
- Guidance and management commentary on GM trajectory and whether 60% is a floor
- R&D as % of revenue trend to confirm continued innovation investment
The composite fair value comes in at $40.23 with a signal-adjusted $41.96, implying about -53% downside from $88.96. The DCF ($29) and EPV floor ($13.30) both scream that the current price bakes in years of continued mid-teens growth, sustained operating leverage, and no serious share loss to Abbott Libre - a heroic set. Only the anchored P/E ($89.60) validates the tape, and that method is essentially circular (it anchors to peer/self multiples that already embed the platform narrative), so it deserves the least weight. Earnings quality is high (score 3), so no haircut is warranted; the business is genuinely strong (quality 65). That raises deserved value versus a mediocre peer, but it does not close a 50%+ gap. Compressing gross margins, a real competitive set, and reimbursement ceilings mean the growth-and-margin trajectory required to justify $89 is closer to the bull case than the base case. Fair, not cheap - and probably somewhat rich. I would want a price in the $60s before the risk/reward turns interesting; below $50 it would look like a genuine bargain against a quality compounder.
Verify before trusting this (4)
- Forward revenue guidance and any commentary on Libre share shifts in the pharmacy channel
- Gross margin bridge - is compression from mix, pricing, or cost, and is it stabilizing
- Reimbursement expansion updates (Type 2 non-insulin, basal) that would extend the runway
- Opex leverage sustainability once revenue growth normalizes below 15%
The tape itself is mildly risk-on, which normally helps a high-beta (1.41) growth med-tech name like DXCM. But the stock-specific press is the other way: the dominant narrative here is 'irreplaceable CGM standard,' and the freshest news flow is explicitly framing Abbott as the better buy on both upside and valuation. That is exactly the kind of headline that chips at a platform-monopoly story whose durability is only 'moderate' and whose cult factor is only 'medium' - there is no fanatic base to absorb the doubt.
Verify before trusting this (4)
- Sell-side target revisions post the Abbott comparison piece - watch for downgrades or preference shifts
- Any G7 vs Libre share-data print in the next quarterly cycle
- Whether the risk-on regime holds beyond a few days or reverses on rates (10y at 4.64%)
- Reimbursement headlines on prediabetic CGM coverage - the linchpin of the TAM story
CGM is one of the few medtech categories where the addressable population is still being redefined upward rather than merely re-priced. The structural forces are reimbursement expansion into non-insulin type 2 and prediabetes, and the normalization of continuous biosensing as a consumer metabolic-health product (Stelo). GLP-1 adoption is, on net, a monitoring tailwind — more patients enter the medical system and are tracked — rather than the demand destruction the bear case implies, since CGM attaches to therapy management, not to disease severity alone. Against that, the world is turning the category into a two-horse commodity race: Abbott's scale in pharmacy distribution and low-cost manufacturing sets the price ceiling, and every new reimbursed cohort arrives at lower revenue-per-patient than the last. Macro is a modest headwind (10y 4.64) but largely irrelevant to a reimbursed consumable. The honest world read: volumes compound for years, revenue per user erodes, and the equilibrium is durable low-double-digit growth with margin as the swing factor — not a hypergrowth inflection.
When we made this prediction on Aug 27, 2026, DXCM was $90.07. We expect it to be $79.00 by Feb 2027, and we consider it great value under $62.00. This is an early model (v0.6.0) — the direction is more reliable than the exact price. Made Aug 27, 2026.
Blue is our prediction, starting the day we made it. Grey is a slower route to the same place — the same destination, taking longer. Black is the actual price, so you can see how we are doing.
Post-Report Due Diligence NOTES
Evidence for a closer look, not a verdict — no score or designation on this page has been changed by it. Items marked material are ones where a conclusion above moves to the other side of the price.
trailing_eps
flips up 25%
adjusted_pe
flips up 25%